Pancreatic Cancer Research

ResearcherRadboud University Medical CenterActive in the last 2 years

Cees J. H. M. van Laarhoven

ORCID-verified (high confidence, 0.95), identity_conf@1As of 8 November 2026

Matched on ORCID iD 0000-0003-2166-7931; OpenAlex author ID A5112250822. Sources: OpenAlex.

Their work

Papers
16 (first author 0, last author 1)
Trials
0
Grants
0
Labs led
0
Collaborators
50
Papers, trials and grants by year

2016: 1 paper · 2017: 3 papers · 2018: none · 2019: 2 papers · 2020: 1 paper · 2021: none · 2022: none · 2023: 1 paper · 2024: 3 papers · 2025: 4 papers · 2026: 1 paper

Papers 16

  1. Continuity of care experienced by patients diagnosed with pancreatic cancer: nationwide multicentre study. Co-author DOI 10.1093/bjsopen/zrag033↗
  2. Delayed gastric emptying after pancreatic cancer surgery impacts time to start of adjuvant treatment but not overall survival: a post-hoc analysis of the PREOP… Co-author DOI 10.1093/bjs/znaf261↗
  3. Intratumoral Holmium-166 Microsphere Injection in Patients with Unresectable Pancreatic Ductal Adenocarcinoma: A Single-Center, Single-Arm, Open-Label Feasibil… Co-author DOI 10.1159/000545246↗
  4. How to Improve Pancreatic Cancer Network Care Using a Human-Centered Design Sprint. Co-author DOI 10.2196/55598↗
  5. Development of an Intratumoral Holmium Microsphere Injection Method in Ex Vivo Human Pancreatic Ductal Adenocarcinoma: A Preclinical Feasibility Study. Co-author DOI 10.3390/cancers17061028↗
  6. Qualitative flow metabolic phenotype of pancreatic cancer. A new prognostic biomarker? Co-author DOI 10.1016/j.hpb.2023.11.010↗
  7. Determinants of treatment decisions of patients with pancreatic cancer in shared decision-making: A qualitative study Co-author DOI 10.22541/au.170670344.49523538/v1↗
  8. Limited Role of the Apparent Diffusion Coefficient (ADC) for Tumor Grade and Overall Survival in Resectable Pancreatic Ductal Adenocarcinoma. Co-author DOI 10.3390/diagnostics14060573↗
  9. Impact of network treatment in patients with resected pancreatic cancer on use and timing of chemotherapy and survival. Co-author DOI 10.1093/bjsopen/zrad006↗
  10. Diagnostic accuracy of contrast-enhanced diffusion-weighted MRI for liver metastases of pancreatic cancer: towards adequate staging and follow-up of pancreatic… Co-author DOI 10.1186/s12885-020-07226-0↗
  11. Improving preoperative detection of synchronous liver metastases in pancreatic cancer with combined contrast-enhanced and diffusion-weighted MRI. Co-author DOI 10.1007/s00261-018-1867-7↗
  12. Optimal respiratory-gated [18F]FDG PET/CT significantly impacts the quantification of metabolic parameters and their correlation with overall survival in patie… Co-author DOI 10.1186/s13550-019-0492-y↗
  13. Nationwide outcomes in patients undergoing surgical exploration without resection for pancreatic cancer. Co-author DOI 10.1002/bjs.10602↗
  14. Nationwide prospective audit of pancreatic surgery: design, accuracy, and outcomes of the Dutch Pancreatic Cancer Audit. Co-author DOI 10.1016/j.hpb.2017.06.010↗
  15. Cost-effectiveness of laparoscopic versus open distal pancreatectomy for pancreatic cancer. Co-author DOI 10.1371/journal.pone.0189631↗
  16. Laparoscopic versus open distal pancreatectomy for pancreatic cancer. Last author DOI 10.1002/14651858.cd011391.pub2↗

Closest collaborators

The 25 strongest of 50 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

  1. Martijn W.J. Stommel · 6 shared papers, 2023–2026 · strength 1.45
  2. John J. Hermans · 6 shared papers, 2019–2025 · strength 1.06
  3. Deniece Rivière · 6 shared papers, 2016–2024 · strength 0.84
  4. Lodewijk A.A. Brosens · 4 shared papers, 2020–2024 · strength 0.77
  5. Marc G. Besselink · 6 shared papers, 2016–2026 · strength 0.67
  6. Jana S. Hopstaken · 3 shared papers, 2023–2026 · strength 0.65
  7. Coen Ysbrand Willink · 2 shared papers, 2025 · strength 0.54
  8. J. Frank W. Nijsen · 2 shared papers, 2025 · strength 0.54
  9. Ignace H. J. T. de Hingh · 4 shared papers, 2017–2026 · strength 0.53
  10. Erwin J. M. van Geenen · 3 shared papers, 2019–2024 · strength 0.44
  11. Pauline A. J. Vissers · 2 shared papers, 2023–2026 · strength 0.41
  12. Judith de Vos‐Geelen · 2 shared papers, 2023–2026 · strength 0.41
  13. Erik H.J.G. Aarntzen · 2 shared papers, 2019–2024 · strength 0.32
  14. Martin Gotthardt · 2 shared papers, 2019–2024 · strength 0.32
  15. Bert A. Bonsing · 2 shared papers, 2017–2026 · strength 0.28
  16. Hjalmar C. van Santvoort · 2 shared papers, 2017–2026 · strength 0.28
  17. Lydia G. van der Geest · 2 shared papers, 2017–2023 · strength 0.25
  18. Theo van Voorthuizen · 1 shared paper, 2025 · strength 0.25
  19. Leonieke Daanen · 1 shared paper, 2024 · strength 0.24
  20. Marion B.M. van der Kolk · 1 shared paper, 2024 · strength 0.24
  21. Philip Jan van der Wees · 1 shared paper, 2024 · strength 0.24
  22. Simone Augustinus · 1 shared paper, 2026 · strength 0.23
  23. Vincent Erwin de Meijer · 1 shared paper, 2026 · strength 0.23
  24. Sebastiaan Festen · 1 shared paper, 2026 · strength 0.23
  25. Hanneke W.M. van Laarhoven · 1 shared paper, 2026 · strength 0.23

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.